By: Norton Healthcare April 17, 2026
By: Norton Healthcare
April 17, 2026
ACNS2321; A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas